The Hindu: A Step Forward in Detection and Prevention of Cancer
Originally published in The Hindu, February 22, 2019.
Lucid Medical Diagnostics has announced a tie-up with MapmyGenome, a molecular diagnostics company, to offer DNA OncoScreen — combining pathology services with genomics for prevention and early detection of cancers.
About 15 kinds of cancer that are more likely to occur among Indians — including breast, lung, prostate, colorectal, bladder, melanoma, renal cell carcinoma, ovarian, thyroid, chronic lymphocytic leukaemia, Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, basal cell carcinoma, and testicular — could be screened using this procedure.
“The screening test will especially be useful for those with a family history of cancer and those who are likely to be prone to cancer owing to their lifestyle.” — Anu Acharya, CEO, MapmyGenome
DNA OncoScreen assesses genetic predisposition to various cancers, physiological traits that are known to trigger cancer, and lifestyles linked to cancer risk with key clinical markers tested. Three comprehensive tests are offered: DNA OncoScreen Pro (₹9,999), DNA OncoScreen Plus (₹15,999), and DNA OncoScreen Premium (₹19,999) — including biochemical tests and genetic risk assessment.
“We will also help in counselling the patients and doctors from certified experts to interpret reports, comprehend lifetime risk, keep track of the body and begin a personalised action plan with diet, lifestyle and other interventions,” said Dr Sunita Lingareddy and Anu Acharya.
Know Your Cancer Risk Before It Knows You
Oncomap by MapmyGenome offers a comprehensive hereditary cancer risk panel. Genomepatri screens for 20+ cancer types from a simple saliva swab. Both include certified genetic counselling and a CAP & NABL-accredited laboratory.
